System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Volkmar Müller is an expert in Oncology at University Medical Center Hamburg-Eppendorf (Germany). As of October 2026, ScienceLeadR ranks Volkmar Müller in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Volkmar Müller has authored 907 publications, the most recent in 2026, and is an investigator in 36 clinical trials, 8 of them ongoing. SLR score: 2,751 (community average: 125). How the SLR is computed.

LeadR Profile

Volkmar Müller University Medical Center Hamburg-Eppendorf Germany
2 751 ScienceLeadR Reputation 2751

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Surgery - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

University Medical Center Hamburg-Eppendorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 907

Citations

Citations: 39 149 1st author: 95 Last author: 112 Unique author: 9

Main journals

Geburtshilfe Frauenheilkd 70
Cancer Res 63
Breast Care (Basel) 55
J Clin Oncol 55
Senologie - Zeitschrift für Mammadiagnostik und -therapie 39

Best Journals

Ann Oncol 21
J Clin Oncol 17
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
CPS + EG and Neo-Bioscore predict individual outcomes but not trial results after neoadjuvant therapy for early breast cancer.
PMID 42945961 — disease-free survival, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics		Cancer Cell Top journal20260
AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer-2026 Update.
PMID 42497646 — breast neoplasms, neoplasms, biomarkers, breast, therapeutics		Breast20262
Incidence and Predictors of Immune-Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real-World Cohort Study.
PMID 42723137 — incidence, melanoma, thyroiditis, neoplasms, cohort studies, thyroid gland, drug therapy, immunotherapy, hypothyroidism, therapeutics, chemotherapy		Int J Cancer20260
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.
PMID 42696691 — circulating tumor dna, breast neoplasms, epigenomics, neoplasms, drug therapy, chemotherapy, adjuvant, breast, precision medicine, therapeutics, tissues, chemotherapy		JCO Precis Oncol20260
Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.
PMID 42557336 — integrins, exosomes, neoplasm metastasis		Nature Top journal20261

Clinical Studies 36

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 23
Phase 2 4
N/A 3
Phase 4 3
Phase 2/Phase 3 2
Phase 1/Phase 2 1

By status:

Completed 22
Active not recruiting 6
Recruiting 6
Not yet recruiting 1
Terminated 1

By type:

Interventional 34
Observational 2

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 2
multicentric5to9 0
multicentricup10 24

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine Versus Tucatinib in Combination with Trastuzumab and Capecitabine in People with Locally Advanced or Metastatic Breast Cancer that is HER2 Positive
2025-524498-17-00 — blood-brain barrier, epidermal growth factor, growth, safety, blood, breast neoplasms, brain, neoplasms, central nervous system, neoplasm metastasis, receptors, growth factor, breast, nervous system, capecitabine, trastuzumab		Phase 2/Phase 3Not yet recruiting2026
TYPER
2024-520290-12-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, mentoring, therapeutics		Phase 4Recruiting2025
To compare the Safety and activity of GDC 4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
2025-521128-31-00 — epidermal growth factor, estrogens, growth, safety, breast neoplasms, receptors, estrogen, cyclin-dependent kinase 4, neoplasms, cyclin-dependent kinases, cyclins, receptors, growth factor, breast, pharmacokinetics		Phase 1/Phase 2Recruiting2025
Comprehensive Analysis of Spatial Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT05452213 — breast neoplasms, neoplasms, hormones, breast, therapeutics		Phase 4Recruiting2022
Study of Sacituzumab Govitecan hziy and Pembrolizumab Versus Treatment of Physician s Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer
NCT05382286 — albumin-bound paclitaxel, triple negative breast neoplasms, breast neoplasms, paclitaxel, neoplasms, breast, therapeutics, carboplatin		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS